Fig. 4: HTRA2 expression is decreased in the brain of tauopathy patients and tauopathy model mice. | Translational Psychiatry

Fig. 4: HTRA2 expression is decreased in the brain of tauopathy patients and tauopathy model mice.

From: Electrophysiology-based screening identifies neuronal HtrA serine peptidase 2 (HTRA2) as a synaptic plasticity regulator participating in tauopathy

Fig. 4

A Comparison of HTRA2 mRNA expression in AD patients (n = 387) and controls (n = 303). Data from NCBI’s Gene Expression Omnibus (Accession number GEO: GSE44772). B Comparison of HTRA2 mRNA expression in the dorsolateral prefrontal cortex of AD patients (n = 202), asymptomatic (Asym) AD patients (n = 204), and controls (n = 125) from the RNA-seq data from ref. [21]. C Comparison of HTRA2 mRNA expression in FLTD-U patients with progranulin mutation patients (n = 15), FLTD-U patients without progranulin mutation patients (n = 24), and controls (n = 17). Data from NCBI’s Gene Expression Omnibus (Accession number GEO: GSE13162). D, E Representative Western blotting and quantification of HTRA2 protein levels in postmortem AD brains and controls (control: n = 5, and AD: n = 6). F, G Representative western blotting and quantification of HTRA2 protein levels in 7-month-old rTg4510 (n = 4 mice per group) and 10-month-old PS19 mouse hippocampal lysates (n = 5 mice per group). A significant difference was determined using the Mann-Whitney test (A), one-way ANOVA with Dunn’s post hoc analysis (B), one-way ANOVA with Tukey’s post hoc analysis (C), and an unpaired t-test (E, F, G). Data represent means ± SEM. *p < 0.05; **p < 0.01; ****p < 0.0001; ns, not significant.

Back to article page